Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b conjugate vaccine (Sanofi)
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DTaP-HB-PRP~T vaccine is a pentavalent combination vaccine developed by Sanofi Pasteur for pediatric immunization. It is designed to provide simultaneous protection against five major infectious diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, and Haemophilus influenzae type b (Hib) infection. The vaccine formulation combines diphtheria and tetanus toxoids, acellular pertussis antigens (DTaP), recombinant hepatitis B surface antigen (HBsAg), and the Hib capsular polyribosyl-ribitol-phosphate (PRP) conjugated to a tetanus toxoid carrier (PRP~T). This combination is particularly intended for use in regions following the WHO Expanded Program on Immunization (WHO-EPI) schedule, where it can be co-administered with the oral polio vaccine (OPV) to reduce the number of required injections. Phase 3 clinical trials have evaluated its immunogenicity and safety as both a primary series and a booster dose in infants and toddlers.
- Other names
- DTaP-HB-PRP~T vaccinepentavalent DTaP-HB-Hib vaccinediphtheria + tetanus + acellular pertussis + hepatitis B + haemophilus influenzae type b conjugate vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)ETV6 (ETS variant transcription factor 6)FHA (Filamentous hemagglutinin)Diphtheria toxinPRNP (Cellular Prion Protein)Poliovirus capsid proteins
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b conjugate vaccine (Sanofi).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + hepatitis B vaccine + haemophilus influenzae type b conjugate vaccine (Sanofi).